Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. (odpre novo okno)

Abdelrazik N, Fouda M

Vir‎: Hematology 2007;12(6):533-41.

Indeksirano‎: PubMed 17852440

DOI‎: 10.1080/10245330701521572

https://www.ncbi.nlm.nih.gov/pubmed/17852440 (odpre novo okno)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (odpre novo okno)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Vir‎: Cancer 2012;118(3):848-55.

Indeksirano‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (odpre novo okno)

Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment. (odpre novo okno)

Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A

Vir‎: Pediatr Hematol Oncol 2008;25(6):509-21.

Indeksirano‎: PubMed 18728970

DOI‎: 10.1080/08880010802235132

https://www.ncbi.nlm.nih.gov/pubmed/18728970 (odpre novo okno)

Recombinant human erythropoietin beta: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. (odpre novo okno)

Durmaz O, Demirkaya M, Sevinir B

Vir‎: Pediatr Hematol Oncol 2011;28(6):461-8.

Indeksirano‎: PubMed 21707225

DOI‎: 10.3109/08880018.2011.570857

https://www.ncbi.nlm.nih.gov/pubmed/21707225 (odpre novo okno)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (odpre novo okno)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Vir‎: J Clin Oncol 2010;28(13):2239-45.

Indeksirano‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (odpre novo okno)

Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. (odpre novo okno)

Hassan BA, Yusoff ZB

Vir‎: Asian Pac J Cancer Prev 2011;12(6):1573-6.

Indeksirano‎: PubMed 22126501

https://www.ncbi.nlm.nih.gov/pubmed/22126501 (odpre novo okno)

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. (odpre novo okno)

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group

Vir‎: Curr Med Res Opin 2009;25(9):2109-20.

Indeksirano‎: PubMed 19601709

DOI‎: 10.1185/03007990903084164

https://www.ncbi.nlm.nih.gov/pubmed/19601709 (odpre novo okno)

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. (odpre novo okno)

Hinds PS, Hockenberry M, Feusner J, Hord JD, Rackoff W, Rozzouk BI

Vir‎: J Support Oncol 2005;3(6 Suppl 4):10-1.

Indeksirano‎: PubMed 16355549

https://www.ncbi.nlm.nih.gov/pubmed/16355549 (odpre novo okno)

The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer. (odpre novo okno)

Hiradfar A, Banihosseinian M

Vir‎: Iran J Ped Hematol Oncol 2014;4(4):151-9.

Indeksirano‎: PubMed 25598955

https://www.ncbi.nlm.nih.gov/pubmed/25598955 (odpre novo okno)

2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. (odpre novo okno)

Marec-Berard P, Chastagner P, Kassab-Chahmi D, Casadevall N, Marchal C, Misset JL, Ray-Coquard I.

Vir‎: Pediatr Blood Cancer 2009;53(1):7-12.

Indeksirano‎: PubMed 19229970

DOI‎: 10.1002/pbc.21953

https://www.ncbi.nlm.nih.gov/pubmed/19229970 (odpre novo okno)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (odpre novo okno)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Vir‎: Cancer 2013;119(1):107-14.

Indeksirano‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (odpre novo okno)

Erythropoietic growth factors for children with cancer: a systematic review of the literature. (odpre novo okno)

Mystakidou K, Potamianou A, Tsilika E

Vir‎: Curr Med Res Opin 2007;23(11):2841-7.

Indeksirano‎: PubMed 17910805

DOI‎: 10.1185/030079907x242601

https://www.ncbi.nlm.nih.gov/pubmed/17910805 (odpre novo okno)

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. (odpre novo okno)

Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR

Vir‎: J Clin Oncol 2006;24(22):3583-9.

Indeksirano‎: PubMed 16877725

DOI‎: 10.1200/JCO.2005.03.4371

https://www.ncbi.nlm.nih.gov/pubmed/16877725 (odpre novo okno)

The role of recombinant erythropoietin in childhood cancer. (odpre novo okno)

Shankar AG

Vir‎: Oncologist 2008;13(2):157-66.

Indeksirano‎: PubMed 18305061

DOI‎: 10.1634/theoncologist.2007-0126

https://www.ncbi.nlm.nih.gov/pubmed/18305061 (odpre novo okno)

Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. (odpre novo okno)

Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, Piedra P, Saurez G, Verdecia M, Cabanas R

Vir‎: MEDICC Rev 2010;12(3):27-31.

Indeksirano‎: PubMed 20697335

DOI‎: 10.37757/MR2010.V12.N3.7

https://www.ncbi.nlm.nih.gov/pubmed/20697335 (odpre novo okno)

A single institutional experience: is epoetin alpha effective in anemic children with cancer? (odpre novo okno)

Yilmaz D, Cetingül N, Kantar M, Oniz H, Kansoy S, Kavakli K

Vir‎: Pediatr Hematol Oncol 2004;21(1):1-8.

Indeksirano‎: PubMed 14660300

https://www.ncbi.nlm.nih.gov/pubmed/14660300 (odpre novo okno)

Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy. (odpre novo okno)

Zachariah M, Elshinawy M, Alrawas A, Bashir W, Elbeshlawi I, Tony S, Wali Y

Vir‎: Pediatr Hematol Oncol 2014;31(5):442-7.

Indeksirano‎: PubMed 24088186

DOI‎: 10.3109/08880018.2013.824527

https://www.ncbi.nlm.nih.gov/pubmed/24088186 (odpre novo okno)

Early epoetin alfa treatment in children with solid tumors. (odpre novo okno)

Zoubek A, Kronberger M

Vir‎: Med Pediatr Oncol 2002;39(4):459-62.

Indeksirano‎: PubMed 12203664

DOI‎: 10.1002/mpo.10186

https://www.ncbi.nlm.nih.gov/pubmed/12203664 (odpre novo okno)

Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. (odpre novo okno)

Crary SE, Hall K, Buchanan GR.

Vir‎: Pediatr Blood Cancer 2011;56(4):615-9.

Indeksirano‎: PubMed 21298748

DOI‎: 10.1002/pbc.22930

https://www.ncbi.nlm.nih.gov/pubmed/21298748 (odpre novo okno)

Intravenous iron sucrose for children with iron deficiency anemia. (odpre novo okno)

Kaneva K, Chow E, Rosenfield CG, Kelly MJ

Vir‎: J Pediatr Hematol Oncol 2017;39(5):e259-62.

Indeksirano‎: PubMed 28562517

DOI‎: 10.1097/MPH.0000000000000879

https://www.ncbi.nlm.nih.gov/pubmed/28562517 (odpre novo okno)

Advances in Pediatric Intravenous Iron Therapy. (odpre novo okno)

Mantadakis E.

Vir‎: Pediatr Blood Cancer 2016;63(1):11-6.

Indeksirano‎: PubMed 26376214

DOI‎: 10.1002/pbc.25752

https://www.ncbi.nlm.nih.gov/pubmed/26376214 (odpre novo okno)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (odpre novo okno)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Vir‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indeksirano‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (odpre novo okno)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (odpre novo okno)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Vir‎: J Clin Oncol 2008;26(10):1619-25.

Indeksirano‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (odpre novo okno)

Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. (odpre novo okno)

Plummer ES, Crary SE, McCavit TL, Buchanan GR

Vir‎: Pediatr Blood Cancer 2013;60(11):1747-52.

Indeksirano‎: PubMed 23832487

DOI‎: 10.1002/pbc.24676

https://www.ncbi.nlm.nih.gov/pubmed/23832487 (odpre novo okno)